A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PLD / phospholipidosis

[Related PubMed/MEDLINE]
Total Number of Papers: 51
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PLD  (>> Co-occurring Abbreviation)
Long Form:   phospholipidosis
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Pathological Features of Corneal Phospholipidosis in Juvenile White Rabbits Induced by Ocular Instillation of Chloroquine or Amiodarone. CADs
2018 Derivatization of common antidepressant drugs increases inhibition of acid sphingomyelinase and reduces induction of phospholipidosis. ASM, CADs, FIASMAs, MDD
2018 Detection of nanocarrier potentiation on drug induced phospholipidosis in cultured cells and primary hepatocyte spheroids by high content imaging and analysis. CAD, DIP, LOPAC, PEG-GO
2017 3D-SDAR modeling of hERG potassium channel affinity: A case study in model design and toxicophore identification. hERG
2017 Arachidonic acid-containing phosphatidylcholine characterized by consolidated plasma and liver lipidomics as an early onset marker for tamoxifen-induced hepatic phospholipidosis. AA, PCs
2017 Dose- and Time-dependency of the Toxicity and Pharmacokinetic Profiles of Bedaquiline and Its N-desmethyl Metabolite in Dogs. BDQ, MDR-TB
2017 From the Cover: Potentiation of Drug-Induced Phospholipidosis In Vitro through PEGlyated Graphene Oxide as the Nanocarrier. CADs, DIP, LAMP2, PEG-GO
2017 Quantitative Assessment of Drug Delivery to Tissues and Association with Phospholipidosis: A Case Study with Two Structurally Related Diamines in Development. ---
2017 Use of the Distribution Coefficient in Brain Polar Lipids for the Assessment of Drug-Induced Phospholipidosis Risk. PAMPA
10  2017 Why are most phospholipidosis inducers also hERG blockers? hERG, PLS, qHTS, ROC
11  2016 Detection of metabolic activation leading to drug-induced phospholipidosis in rat hepatocyte spheroids. NBD-PE
12  2016 Establishment of an in silico phospholipidosis prediction method using descriptors related to molecular interactions causing phospholipid-compound complex formation. MR, PL
13  2016 Hepatic Phospholipidosis Is Associated with Altered Hepatobiliary Function as Assessed by Gadoxetate Dynamic Contrast-enhanced Magnetic Resonance Imaging. ALP, AST, DCE-MRI
14  2016 Method development and validation for simultaneous quantitation of endogenous hippuric acid and phenylacetylglycine in rat urine using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. HA, PAG
15  2015 Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach. CADs
16  2015 Molecular biomarkers of phospholipidosis in rat blood and heart after amiodarone treatment. AMD
17  2015 Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach. HCS
18  2014 A novel mixed phospholipid functionalized monolithic column for early screening of drug induced phospholipidosis risk. ---
19  2014 Computational identification of a phospholipidosis toxicophore using (13)C and (15)N NMR-distance based fingerprints. ---
20  2014 How does the quality of phospholipidosis data influence the predictivity of structural alerts? EM, SMARTS
21  2014 Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substrates. AMD, AZI, CHQ, DES, GTM, RSV, SCH, TC
22  2014 Liposome electrokinetic chromatography based in vitro model for early screening of the drug-induced phospholipidosis risk. LEKC
23  2014 One man's poison is another man's meat: using azithromycin-induced phospholipidosis to promote ocular surface health. AZM, DED, HMGEC, MGD
24  2014 Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B Inhibitor. ---
25  2013 Are hERG channel blockers also phospholipidosis inducers? hERG, qHTS
26  2013 Increased levels of urinary phenylacetylglycine associated with mitochondrial toxicity in a model of drug-induced phospholipidosis. NMR, uPAG
27  2013 Modeling phospholipidosis induction: reliability and warnings. PLS-DA
28  2013 pH-gradient PAMPA-based in vitro model assay for drug-induced phospholipidosis in early stage of drug discovery. CADs
29  2012 Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals. EKC, PLIP
30  2012 Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat. ---
31  2012 Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats. ---
32  2012 Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds. CAD, DfW, LPDM
33  2012 Identification of drugs inducing phospholipidosis by novel in vitro data. ---
34  2012 In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. AM
35  2012 In vitro validation of drug-induced phospholipidosis. ---
36  2012 Structure based model for the prediction of phospholipidosis induction potential of small molecules. AUC-ROC, LOPAC, MOE, NCGC, qHTS, SVM
37  2011 Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis. ---
38  2011 Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential. ---
39  2011 In Silico Studies of the Relationship Between Chemical Structure and Drug Induced Phospholipidosis. CADs
40  2010 Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. ---
41  2009 Characterization of the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives. CADs
42  2009 Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats. ---
43  2009 Screening for the drug-phospholipid interaction: correlation to phospholipidosis. ---
44  2008 Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes. CADs
45  2008 Monitoring the accumulation of fluorescently labeled phospholipids in cell cultures provides an accurate screen for drugs that induce phospholipidosis. CADs
46  2008 Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE. NBD-PE
47  2007 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. ---
48  2007 In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. ---
49  2007 Urinary metabolic fingerprinting for amiodarone-induced phospholipidosis in rats using FT-ICR MS. AMD, FT-ICR MS, HA, IDN, PAG, PCA
50  2006 Validation of an in vitro screen for phospholipidosis using a high-content biology platform. NBD-PE
51  2003 Characterisation of a potential biomarker of phospholipidosis from amiodarone-treated rats. BMP, CAD, ESI-MS, HPLC, LBPA, LC, PCA, PLs